Dapagliflozin: all 489 studies that test it
Page 1 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin ResistanceNot yet recruitingNCT07891234Phase 4
- Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid ArthritisNot yet recruitingNCT07864688Phase 2
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingNCT07848191Phase 4
- Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary SyndromeNot yet recruitingNCT07810998Phase 2/3
- Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLDNot yet recruitingNCT07778719Not applicable
- aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)Not yet recruitingNCT07741890Phase 2
- Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingNCT07729592Phase 2
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"RecruitingNCT07684326Phase 2/3
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruitingNCT07662109Phase 3
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusRecruitingNCT07662044Phase 3
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)RecruitingNCT07624305Phase 3
- SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in DiabetesRecruitingNCT07614230Phase 4
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"Not yet recruitingNCT07598864Phase 3
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
- Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic StenosisNot yet recruitingNCT07539259Phase 2
- Dapagliflozin for Anemia in Lower-Risk Myelodysplastic SyndromesNot yet recruitingNCT07516847Phase 2
- Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric SurgeryEnrolling by invitationNCT07515391Phase 2
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo CardiomyopathyRecruitingNCT07491718Not applicable
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.RecruitingNCT07491042Not applicable
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory DysfunctionNot yet recruitingNCT07488689Phase 3
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureRecruitingNCT07482943Phase 4
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney DiseaseRecruitingNCT07405216Phase 4
- The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart FailureNot yet recruitingNCT07403955Not applicable
- CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HFNot yet recruitingNCT07351643Phase 4
- Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled TrialNot yet recruitingNCT07342764Phase 4
- Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial FibrillationNot yet recruitingNCT07331727Not applicable
- Dapagliflozin in Active Lupus NephritisRecruitingNCT07323524Phase 4
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)Not yet recruitingNCT07311551Phase 4
- Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate CancerNot yet recruitingNCT07310433Phase 2
- Epicardial Cardiac Fat-CT (EPIC-CT)RecruitingNCT07297589Phase 3
- Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)RecruitingNCT07295223Phase 3
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseRecruitingNCT07280585Phase 3
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal SyndromeRecruitingNCT07273838Phase 2
- Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetesRecruitingNCT07254572Phase 4
- Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer PatientsRecruitingNCT07245069Phase 2
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney DiseaseRecruitingNCT07239570Phase 4
- Dapagliflozin in DepressionRecruitingNCT07239011Phase 1/2
- Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung AdenocarcinomaRecruitingNCT07235280Early Phase 1
- Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using DapagliflozinNot yet recruitingNCT07225465Phase 2
- SGLT2 Inhibitors in Adult Primary Nephrotic SyndromeRecruitingNCT07214818Phase 2/3
- RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual CareRecruitingNCT07187570Phase 3
- SGLT2 Inhibitors in Geographic AtrophyRecruitingNCT07174687Phase 2
- Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous NephropathyNot yet recruitingNCT07096986Phase 2
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)RecruitingNCT07083401Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)RecruitingNCT07083388Phase 1
- Dapagliflozin for Cardio-renal Protection After ICU DischargeRecruitingNCT07025629Phase 3
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy ToxicityRecruitingNCT07018622Phase 2
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney DiseaseRecruitingNCT06982079Phase 3
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyEnrolling by invitationNCT06954090Phase 4
- Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized StudyRecruitingNCT06929169Phase 2
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?Not yet recruitingNCT06922656Phase 4
- Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic AscitesNot yet recruitingNCT06919523Phase 2
- Dapagliflozin for Long COVID SyndromeNot yet recruitingNCT06907251Phase 3
- Impact of Dapagliflozin in Anemic Chronic Kidney Disease PatientsRecruitingNCT06897605Phase 2
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)RecruitingNCT06887062Phase 2
- Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular EdemaRecruitingNCT06845163Phase 2
- Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKDNot yet recruitingNCT06820567Phase 3
- A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)RecruitingNCT06785116Phase 4
- Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart FailureRecruitingNCT06783166Phase 2/3
- CAMEO-FONTAN -Dapagliflozin in the Failing Fontan CirculationRecruitingNCT06762964Phase 2
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruitingNCT06742723Phase 3
- Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based ChemotherapyRecruitingNCT06711185Phase 3
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruitingNCT06677060Phase 3
- Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status TrialRecruitingNCT06668389Phase 4
- A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordRecruitingNCT06642272Phase 4
- Dapagliflozin in Allo-HCT for aGVHDRecruitingNCT06626737Phase 2
- Dapagliflozin in Mangement of Pulmonary Hypertension PatientsNot yet recruitingNCT06612086Phase 1
- Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary SyndromeRecruitingNCT06576375Phase 3
- STunning in Acute Myocardial Infarction - BASRecruitingNCT06562582Phase 4
- Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney TransplantationRecruitingNCT06560801Phase 4
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRecruitingNCT06528405Phase 2
- Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection FractionNot yet recruitingNCT06510270Not applicable
- Cardiotoxicity in Breast Cancer PatientsRecruitingNCT06491680Phase 4
- SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HFNot yet recruitingNCT06442280Phase 4
- IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron DeficiencyNot yet recruitingNCT06434025Phase 3
- Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced CardiotoxicityRecruitingNCT06427226Phase 2
- Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease PatientsRecruitingNCT06421870Phase 3
- DapagliFLOzin in Renal AL Amyloidosis (FLORAL)RecruitingNCT06420167Phase 2
- Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis PatientsRecruitingNCT06398977Not applicable
- The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis PatientsRecruitingNCT06365541Phase 4
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes MellitusRecruitingNCT06364930Phase 4
- Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced CardiotoxicityRecruitingNCT06341842Phase 2
- CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIALRecruitingNCT06304857Phase 3
- Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary SyndromesRecruitingNCT06286878Phase 2/3
- Treatment of Patients With Diabetic Kidney DiseaseNot yet recruitingNCT06187493Not applicable
- Dapagliflozin in STEMIRecruitingNCT06174753Phase 3
- SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney DiseaseRecruitingNCT06155604Phase 2
- To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated CirrhosisNot yet recruitingNCT06147518Not applicable
- Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant RecipientsRecruitingNCT06140537Phase 4
- Assessment of Safety and Efficacy of SGLT2is Among LN PatientsNot yet recruitingNCT06113900Phase 1/2
- dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized EvaluationNot yet recruitingNCT06072326Phase 2
- SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With PrediabetesRecruitingNCT06054035Phase 4
- Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose RationaleNot yet recruitingNCT06012266Phase 2
- Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMIRecruitingNCT06009874Not applicable
- Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyRecruitingNCT05989347Phase 1
- Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI PatientsRecruitingNCT05957887Phase 3
- Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsRecruitingNCT05944016Phase 3
- The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant RecipientsRecruitingNCT05938712Phase 2
- Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and SafetyRecruitingNCT05915949Phase 4
- Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic PatientsNot yet recruitingNCT05914857Phase 2